Harmony Biosciences Holdings (HRMY)

Harmony Biosciences Holdings, Inc. (HRMY) is a commercial-stage pharmaceutical company that focuses on addressing overlooked needs in the treatment of rare, neurological disorders. Incorporated in Delaware, the company’s primary operations are headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences was founded by Marc Barbier in 2017 with the vision of bringing innovation to patient care. This aspiration is reflected in the company’s commitment to developing and bringing innovative pharmaceutical products to market, particularly those that serve the underserved patient populations affected by rare neurological disorders.

The company's key product is a product marketed under two different brands in the U.S., WAKIX® and WAKIX® for paediatric use. Both brands are used in the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult and paediatric patients with narcolepsy. This drug was the first and remains the only product approved by the US Food and Drug Administration (FDA) to address both major symptoms in this patient population.

Harmony Biosciences' strategic approach to the discovery, development, and marketing of pharmaceutical drugs is strongly research-focused and patient-centric, ensuring that their efforts align with the needs of the patients they aim to serve. Their keen attention to the development and delivery of treatment options that improve the patient's quality of life has made Harmony Biosciences a pioneer in the niche sector of rare neurological disorders.

In addition to their commitment to patient care, Harmony Biosciences also invests considerable resources into community initiatives and public education. They maintain robust relationships with patient advocacy groups and healthcare providers, engaging in regular dialogue to better understand patients' needs and fill in any gaps in treatment.

Financially, the company has shown promising growth since its inception. With the successful launch of WAKIX®, Harmony Biosciences reported total revenues of $128.4 million for its third quarter in 2020. The company’s performance can be attributed to its strong commitment to ground-breaking research and development and its focus on meeting unmet medical needs.

Harmony Biosciences’ mission clearly centres on fostering a culture that drives innovation with an unwavering commitment to helping patients live their best possible lives. The company’s dedication to improving patient outcomes, coupled with its unique focus on rare neurological conditions, positions it as a significant player in the pharmaceutical industry. As a company driven by the power of empathy and a belief in the power of harmonic science to transform lives, Harmony Biosciences has already made a significant impact and promises to continue doing so.